VS-7375 Demonstrates 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) October 20, 2026
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer October 20, 2026
GOBLET Ph 1/2 study Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in H1 2027 October 20, 2026
RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer October 20, 2026
Positive Topline Results from Interim Analysis of Ph 3 ACTION-1 for RYZ101 Announced in Patients with GEP-NETs October 14, 2026
First Patient dosed in Ph 3 RASolute 309 Trial of RASONQUE™ (daraxonrasib) + Zoldonrasib in 1L Metastatic RAS G12D Pancreatic Cancer October 14, 2026
Results from VIRAGE Ph 2b Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine October 6, 2026
US FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) + Chemo for 1L Metastatic Pancreatic Cancer September 22, 2026
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy September 9, 2026
AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039 September 9, 2026
DB-1317 Granted FDA Fast Track Designation for Treatment of Advanced Pancreatic Ductal Adenocarcinoma September 2, 2026
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer September 2, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer August 25, 2026
FDA Fast Track Designation Granted to ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma August 25, 2026
Patient enrollment completed in Ph 3 TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer August 20, 2026
Olomorasib receives FDA Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer August 5, 2026
IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers August 5, 2026
Final subject received last dose of Ampligen (rintatolimod) in Ph 2 DURIPANC trial of Ampligen + Imfinzi for the treatment of metastatic pancreatic cancer August 5, 2026
FDA accepts NDA for Daraxonrasib for Review for Previously Treated Metastatic Pancreatic Cancer July 28, 2026
Enrollment completed in Ph 2 trial of spevatamig + chemo for the 1L metastatic pancreatic ductal adenocarcinoma July 28, 2026
Ph 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease July 7, 2026
